Autolus Therapeutics plc ADR (NASDAQ: AUTL) on Tuesday, plunged -6.29% from the previous trading day, before settling in for the closing price of $1.59. Within the past 52 weeks, AUTL’s price has moved between $1.11 and $3.08.
Healthcare Sector giant saw their annual sales surged by 21.35% over the last five years. The company achieved an average annual earnings per share of -12.14%. With a float of $240.34 million, this company’s outstanding shares have now reached $266.14 million.
Autolus Therapeutics plc ADR (AUTL) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Autolus Therapeutics plc ADR is 9.70%, while institutional ownership is 51.21%.
Autolus Therapeutics plc ADR (AUTL) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.09 earnings per share (EPS) for the period topping the consensus outlook (set at -0.24) by 0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.56% during the next five years compared to 21.35% growth over the previous five years of trading.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Autolus Therapeutics plc ADR (AUTL) is currently performing well based on its current performance indicators. A quick ratio of 5.82 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Analysing the last 5-days average volume posted by the [Autolus Therapeutics plc ADR, AUTL], we can find that recorded value of 2.75 million was better than the volume posted last year of 2.49 million. As of the previous 9 days, the stock’s Stochastic %D was 72.08%.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 19.33%, which indicates a significant decrease from 63.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0993 in the past 14 days, which was lower than the 0.1143 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4940, while its 200-day Moving Average is $1.7290. Now, the first resistance to watch is $1.5400. This is followed by the second major resistance level at $1.5900. The third major resistance level sits at $1.6200. If the price goes on to break the first support level at $1.4600, it is likely to go to the next support level at $1.4300. Now, if the price goes above the second support level, the third support stands at $1.3800.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
Market capitalization of the company is 396.55 million based on 266,143K outstanding shares. Right now, sales total 10,120 K and income totals -220,660 K. The company made 21,190 K in profit during its latest quarter, and -79,120 K in sales during its previous quarter.
